Id: CBI_2212 | Pages: 289 | Format : PDF | Published : | Author : Amit Sati | Category : Healthcare
HIDA Scan Market size is growing with a CAGR of 6.4% during the forecast period (2025-2032), and the market is projected to be valued at USD 507.02 Million by 2032 from USD 309.00 Million in 2024.
HIDA scan stands for hepatobiliary iminodiacetic acid scan. It is also known as hepatobiliary scintigraphy. It is a nuclear medicine imaging test used to check the functioning of different organs. These organs include liver, gallbladder, bile ducts, and small intestines. During this medical test, a small amount of safe radioactive substance is injected into bloodstream of the human body. The substance then moves to the liver and into other organs. This allows a special camera called gamma camera to take pictures as it moves through the body.
Doctors use this scan to diagnose various conditions. It helps doctors to identify inflammation in gallbladder. Moreover, it helps in identifying blockages in bile ducts. It also helps in checking if there is any leakage from the bile duct. In addition, this scan also shows functioning and complications after surgery like live transplant. Furthermore, it is useful in identifying issues such as biliary atresia. The scan is beneficial as it provides detailed information about patient's condition.
Due to increased busy lifestyles, unhealthy eating habits are observed globally. The individuals are relying on fast food and are eating a lot of processed foods. The consumption of alcohol is also increased. The dedicated amount of time for exercise is reduced. These trends have increased obesity rates. Due to this, individuals are facing more issues with their liver, gallbladder and bile ducts. This has increased cases of hepatobiliary disorders requiring hepatobiliary iminodiacetic acid scan for effective diagnosis.
For instance,
Overall, the rising prevalence of hepatobiliary disorders is significantly boosting the HIDA scan market expansion.
There has been a shift in approaches in individuals towards their health. More people are becoming aware of the benefits of catching health issues in early stage before they get serious. This awareness is due to educational campaigns conducted by healthcare organizations. Moreover, patients are also becoming aware of various diseases and what diagnostic procedures are available for it. This has been possible through information provided by different communication platforms.
For instance,
Thus, growing awareness of early diagnosis is accelerating the global HIDA scan market growth.
The approval process of devices and drugs used in scan requires rigorous testing. It makes sure that manufacturers comply with stringent regulatory standards. This includes clinical trials such as phase 1, phase 2 and others. These clinical trials are necessary by the regulatory body to ensure devices or drugs used in scan are safe and effective.
Moreover, the regulatory process varies in every country and region. For example, globally there are different regulatory bodies such as FDA, EMA, or others. These agencies have different requirements. This creates barriers for companies who aim for international commercialization. In addition, manufacturers face financial and operational problems due to post-approval pharmacovigilance requirements. Furthermore, strict rules against disposal of radioactive material also create challenges. Hence, regulatory hurdles are hampering the HIDA scan market demand.
Advancements in technology are creating potential for the market. Radiopharmaceuticals are drugs used to examine bile flow. There is development of advanced radiopharmaceutical which is more safer. The precision which helps doctors to get clear images is also improved. This improved precision is leading to early diagnosis of health conditions. Moreover, gamma cameras are used to take images of different organs such as liver and gallbladder. Advancements in these cameras are also proving beneficial for the scan.
For instance,
Based on application, the market is categorized into cholecystitis, bile duct obstruction, biliary atresia, postoperative complications, and others.
Trends in Application:
The cholecystitis segment accounted for the largest market share of 48.79% in 2024.
The biliary atresia segment is expected to grow at the fastest CAGR over the forecast period.
Based on end-use, the market is categorized into hospitals & clinics, diagnostic centers, and others.
Trends in the End-Use:
The hospitals & clinics segment accounted for the largest market share in 2024.
The diagnostic centers segment is expected to grow at the fastest CAGR over the forecast period.
The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2024, North America accounted for the highest HIDA scan market share at 42.22% and was valued at USD 130.46 Million and is expected to reach USD 204.00 Million in 2032. In North America, the U.S. accounted for the HIDA scan market share of 71.16% during the base year of 2024. In the region, more people are being diagnosed with hepatobiliary disorders. These disorders include issues related to gallbladder, liver, and bile duct. Poor diet and obesity are the factors which are making these disorders common in this region. Owing to the rise in these conditions, doctors are relying on HIDA scan to avoid misdiagnosis. These scans also help medical professionals in diagnosing these conditions early. Moreover, the region is increasing its manufacturing capabilities due to increased demand.
For instance,
Overall, the rising prevalence of hepatobiliary disorders and expansion of radiopharmaceutical manufacturing is driving the market in region.
In Asia Pacific, the HIDA scan market is experiencing the fastest growth with a CAGR of 7.6% over the forecast period. The market is driven by several trends. People in this region are becoming more informed about the importance of catching health problems early. Campaigns by healthcare industry providers and government are helping people to get educated more on diagnostic procedures such as HIDA scan. They are making people aware that diagnosis improves treatment outcomes which reduces long-term healthcare costs to patients. At the same time, the region is expanding its diagnostic centers. Governments are making sure that rural areas have also access to these diagnostic procedures. Morever, many centers in the region are offering specialized imaging services. This makes the scan accessible to more population. Also, they offer affordable and faster service, which appeals to patients more.
Europe's HIDA scan market analysis states that several trends are responsible for the progress of the market in the region. Procedures that required hospitalization are now performed in outpatient settings. This has led healthcare providers in Europe to shift towards outpatient care as well. These centers before operating surgeries check if individuals are not suffering any other health issues. This has boosted the demand of hepatobiliary scintigraphy. Moreover, reimbursement policies in European countries have made these scans accessible. Public and private health insurance covers a significant amount of diagnostic imaging costs. This financial support encourages patients to undergo these procedures. It also motivates healthcare industry to invest in advanced diagnostic technologies.
The Middle East and Africa (MEA) HIDA scan market analysis states that the region is also witnessing several trends for notable surge. In the region, many countries are investing in modernizing hospitals. New hospitals are equipped with advanced diagnostic tools. This is making specialized procedures such as hepatobiliary scintigraphy more accessible to patients. These improvements are especially observed in urban areas, as that area has a high need for diagnostic services. Morever, governments are taking many initiatives in the region. They are doing funding programs to improve healthcare access. These efforts include subsidizing diagnostic equipment and training healthcare professionals. In addition, newer radiopharmaceuticals are enhancing the accuracy of these tests.
Latin America's HIDA scan market size is also emerging and limited retail penetration in rural areas poses challenges. Hospitals and diagnostic centers in the region are adopting newer technologies. This adoption includes integrating AI technology. It helps in enhancing imaging precision. This is also beneficial in speeding up diagnostic procedures. Moreover, the region is having more collaboration between healthcare providers and global technology companies. These partnerships are making diagnostic tools more accessible required for this scan. With better access to diagnostic tools, hospitals are now offering high-quality diagnostic services, which also include hepatobiliary iminodiacetic acid scan. This teamwork is helping to address the growing demand for diagnostic solutions.
The HIDA Scan market is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D) and product innovation to hold a strong position in the global HIDA Scan market. Key players in The HIDA Scan industry include-
Report Attributes | Report Details |
Study Timeline | 2019-2032 |
Market Size in 2032 | USD 507.02 Million |
CAGR (2025-2032) | 6.4% |
By Application |
|
By End Use |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
In 2024, the HIDA Scan market is USD 309.00 Million.
Asia Pacific is the fastest-growing region in the HIDA Scan market.
Application and End-Use segmentation details are covered in the HIDA Scan market
GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (Netherlands), Digirad Corporation (U.S.), DDD Diagnostics A/S (Denmark), Toshiba Medical Systems (Japan), Serac Imaging Systems (UK), and Cardinal Health, Inc. (U.S.)